Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | CETP | P11597 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397781 | 0.89 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1CETPTSHR | |
| SCHEMBL417168 | 0.88 | CETP (0.50) | ALDH1A1MAPK1L3MBTL1CETPTSHR | |
| SCHEMBL13966888 | 0.86 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1CETPTSHR | |
| SCHEMBL3047517 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1CETPTSHR | |
| SCHEMBL4465319 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1TSHRTDP1 | |
| SCHEMBL11123448 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1CETPTSHR | |
| SCHEMBL5895627 | 0.84 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1KMT2AMAPT | |
| SCHEMBL11307576 | 0.83 | TSHR (0.51) | ALDH1A1MAPK1CETPTSHRKMT2A | |
| SCHEMBL6915874 | 0.81 | MAPK1 (0.48) | ALDH1A1MAPK1L3MBTL1CETPTSHR | |
| SCHEMBL413305 | 0.81 | TSHR (0.58) | ALDH1A1MAPK1L3MBTL1CETPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562001-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | Nura Bio, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024026368-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-2800738-B1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NOVARTIS AG (CH) | 2020-04-08 | — | — | EP | disclosed |
| CN-107011229-B | The application method of heterocyclic compound and they | 诺华股份有限公司 | 2019-11-05 | — | — | CN | disclosed |
| US-10370388-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| EP-0590789-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5284957-A | Substituted 1H- or 2H-tetrazoles | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| EP-0345997-A2 | Azetidinone intermediates for 1-carba (dethia) cephalosporins | ELI LILLY AND COMPANY (US) | 1989-12-13 | — | — | EP | disclosed |
| EP-0345998-A1 | Process and intermediates for beta-lactam antibiotics | ELI LILLY AND COMPANY (US) | 1989-12-13 | — | — | EP | disclosed |
| US-4885362-A | Azetidinone intermediates for 1-carba(dethia)caphalosporins | ELI LILLY AND COMPANY (US) | 1989-12-05 | — | — | US | disclosed |
| US-4820815-A | USEFUL AS ANTIBACTERIALS OR TO FORM FUSED BICYCLIC B-LACTAM ANTIBIOTICS LIKE CARBAPENEMS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0306266-A1 | Azetidinone n-phosphonomethyl esters | THE UNIVERSITY OF NOTRE DAME DU LAC (US) | 1989-03-08 | — | — | EP | disclosed |
| US-4599330-A | 24,24-DIFLUORO-1,25-DIHYDROXYCHOLECALCIFEROL | HOFFMANN-LA ROCHE INC. (US) | 1986-07-08 | — | — | US | disclosed |
| US-4421690-A | ANTI-RACHITOGENIC | HOFFMANN-LA ROCHE INC. (US) | 1983-12-20 | — | — | US | disclosed |
| US-4397847-A | OF OSTEOPOROSIS WITH 24,24-DIFLUORO-1,25-DIHYDROXYCHOLECALCIFEROL | HOFFMANN-LA ROCHE INC. (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | ALDH1A1 2774/4885MAPK1 269/4885L3MBTL1 2478/4885 |
| US-10370388-B2 | Heterocyclic compounds and methods of their use | AGTR2, AGTR1, BDKRB2 | ALDH1A1 2974/4885MAPK1 657/4885L3MBTL1 4805/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | ALDH1A1 2630/4885MAPK1 204/4885L3MBTL1 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.